Diabetes Drug Market Research Report- Forecast to 2023

Diabetes Drug Market Research Report – Global Forecast to 2023

ID: MRFR/HC/0654-HCRR | April, 2018 | Region: Global | 80 pages | Half-Cooked Research Reports

Global Diabetes Drug Market Research Report, Type of Diabetes (Type-1 And Type-2), By Administration (Oral, Intravenous, Other), By Drug Class (Insulin, Sensitizers, SGLT-2 Inhibitors, Alpha-Glucosidase Inhibitors), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast to 2023

Market Scenario

Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two type of diabetes namely type-1 diabetes and type-2 diabetes. During last decade there is a tremendous increase in the number of diabetic population. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. A number of different types of drugs are available in the market however, no available treatment can cure diabetes totally. The global diabetic drug market is majorly driven by increasing number of diabetic population. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. To meet the increasing demand for the drugs government of different countries are providing support to manufacturers. Increasing government support will help to boost the market in coming future. However, cost issues, strict regulatory rules and long approval time for drugs may led to restrain the growth of the market.

The global diabetes drug market is expected to grow at a CAGR of 6.38% during forecasted period.

Intended Audience

Government and Private Hospitals

Blood banks and institutes

Biotechnological institutes

Pharmaceutical companies

Research and Development (R&D) Companies

Market Research and Consulting Service Providers

Medical Research Laboratories

Figure 1:- Global diabetes drug market share, by region

Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The global diabetes drug market is segmented on the basis of types, route of administration, drug class, and end users.

On the basis of types, the market is segmented into type-1 diabetes and type-2 diabetes.

On the basis of route of administration, the market is segmented into oral, intravenous and other.

On the basis of drug class they are insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others. Sensitizers are sub segmented into thiazolidinediones and biguanides. Secretagogues are further segmented into sulfonylureas and non-sulfonylureas

On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics and other.

Regional Analysis

America dominates the global diabetes drug market owing to large diabetic patient population. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Furthermore, increasing awareness among the people regarding different monitoring procedures, rising awareness and well-developed technology have also contributed to the growth of the market.

Europe accounts for the second largest diabetes drug market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market in Europe.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.

On the other hand, the Middle East & Africa has the least share in the global diabetes drug market due to presence of poor economy especially in Africa region. Middle East holds the major share in the Middle East & Africa diabetes drug market owing to well-developed healthcare sector and huge healthcare expenditure.

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation

Key Players for global diabetes drug market

The major player in the global diabetic drug market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan)

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Diabetes Drug Market, by Type

6.1 Introduction

6.2 Type-1 Diabetes